How ReceptivaDx™ Treats Endometriosis Successfully

Pregnant Woman in SummerMy fertility practice is one of the few that is using ReceptivaDx™ - an extremely useful diagnostic test that I have been using for the last year to accurately detect inflammatory conditions in the pelvis or uterine lining and undiagnosed endometriosis. The test specifically identifies BCL6, a gene biomarker that is present in the setting of inflammation and/or endometriosis.


Gene expression of BCL6 protein is significantly over-expressed in women with endometriosis, causing "progesterone resistance" that may contribute to implantation failure. Thus, we use this non-surgical test, which is done through an endometrial biopsy during an office visit. ReceptivaDx™ may help many women with unexplained infertility, undiagnosed endometriosis, or repeated IVF implantation failures even though they may have high quality embryos and proper embryo transfer timing, based on ERA -Endometrial Receptivity Assessment testing.

Big News

Now, there is some big news regarding women with elevated BCL6 and the effectiveness of medical or surgical treatment. Previous studies demonstrated that women with abnormal BCL6 expression - meaning a positive result from their ReceptivaDx™ test - had less than an 11 percent chance of success with in vitro fertilization (IVF) if they did not have any treatment. A recent study, published in the Journal of Assisted Reproduction and Genetics, found that if these women were treated surgically or medically, the success rate leading to a live birth goes up to greater than 50 percent on the next transfer cycle.

The study also demonstrated significantly lower miscarriage rates for patients who received treatment compared to a control group that was left untreated. 

How the Study Was Done

A prospective cohort study was performed over a seven-year period from 2011-2018. The study included women ages 27 to 42 who had at least one year of unexplained infertility along with other qualifying parameters to ensure a uniform patient mix. All subjects were tested for BCL6 (ReceptivaDx) via an endometrial biopsy. 

For those women with elevated BCL6 results, the treatment groups were divided into surgical (laparoscopy) treatment of endometriosis or inflammatory conditions or medical suppression with a GnRH agonist such as Lupron for two months. Both groups were compared to a control cohort that did not receive treatment. Because there was dramatic improvement in clinical pregnancy rates and live birth rates, as well as a reduction in miscarriage rates among those who were treated, the researchers say that undiagnosed endometriosis may play a much larger role than previously thought with regards to IVF outcomes following fresh or frozen embryo transfers. 

Click here to read Dr. Jacobs’ previous article about Endometriosis and ReceptivaDx™ testing.

I have been performing the cutting edge ReceptivaDx™ test at the Fertility Centers of Illinois Buffalo Grove and Hoffman Estates offices for more than a year with great success! This new study supports what we are already experiencing by identifying women with abnormal BCL6 and treating them before proceeding to another IVF cycle. Unexplained infertility is a frustrating diagnosis for couples, and by using this test and treating the inflammation or undiagnosed endometriosis, we can help many couples successfully build their families.

The Endometriosis Doctor

Using the ReceptivaDx™ test – Dr. Laurence Jacobs wants to help you overcome infertility due to endometriosis. The Infertility Doctor has two beautiful offices located Hoffman Estates IL and Buffalo Grove IL.

Click the icon below to schedule your consultation with Dr. Laurence Jacobs – or – call 888.325.7389.Click Here To Schedule Your Consultation  With Dr. Laurence Jacobs